Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269374 | 0.96 | PDK2 (0.36) | PIK3CDHRH4LRRK2KCNH2SCN5A | |
| SCHEMBL31269386 | 0.91 | HRH4 (0.32) | PIK3CDHRH4LRRK2 | |
| SCHEMBL31269168 | 0.91 | PDK2 (0.38) | PIK3CDHRH4LRRK2PDK2NPC1 | |
| SCHEMBL31269082 | 0.89 | PIK3CD (0.36) | PIK3CDHRH4KCNH2SCN5ASCN9A | |
| SCHEMBL31269116 | 0.88 | ESR1 (0.38) | HRH4DRD2 | |
| SCHEMBL31268950 | 0.87 | KCNH2 (0.32) | PIK3CDHRH4KCNH2SCN5ASCN9A | |
| SCHEMBL30983456 | 0.87 | PIK3CD (0.35) | PIK3CDHRH4KCNH2SCN5ASCN9A | |
| SCHEMBL30984004 | 0.87 | KCNH2 (0.32) | PIK3CDHRH4KCNH2SCN5ASCN9A | |
| SCHEMBL31269061 | 0.87 | MET (0.33) | PIK3CDHRH4LRRK2KCNH2SCN5A | |
| SCHEMBL31268935 | 0.86 | PDE2A (0.34) | PIK3CDHRH4KCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |